Elevation Oncology Income Statement

Financials in millions SGD. Fiscal year is January - December.

Millions SGD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	71.12	74.67	47.48	27.98
Revenue Growth (YoY)	34.12%	57.28%	69.69%	-
Cost of Revenue	61.34	63.51	36.52	25.09
Gross Profit	9.78	11.16	10.95	2.89
Selling, General & Admin	3.8	3.24	1.43	0.8
Operating Expenses	4.02	3.46	1.53	0.88
Operating Income	5.76	7.7	9.43	2.01
Interest Expense	-0.29	-0.15	-0.04	-0.03
Interest & Investment Income	0.11	0.11	0.04	-
Earnings From Equity Investments	2.34	1	0.06	0.01
Other Non Operating Income (Expenses)	0.08	0.65	0.12	0.13
EBT Excluding Unusual Items	8.01	9.32	9.61	2.13
Other Unusual Items	1.08	1.08	-1.02	-
Pretax Income	9.08	10.39	8.59	2.13
Income Tax Expense	1.19	1.44	1.76	0.36
Net Income	7.89	8.96	6.83	1.77
Net Income to Common	7.89	8.96	6.83	1.77
Net Income Growth	11.57%	31.09%	286.59%	-
Shares Outstanding (Basic)	348	343	339	262
Shares Outstanding (Diluted)	348	344	339	262
Shares Change (YoY)	-4.23%	1.51%	29.05%	-
EPS (Basic)	0.02	0.03	0.02	0.01
EPS (Diluted)	0.02	0.03	0.02	0.01
EPS Growth	16.23%	28.89%	199.60%	-
Free Cash Flow	4.52	9.24	5.87	-0.8
Free Cash Flow Per Share	0.01	0.03	0.02	-0.00
Dividend Per Share	0.006	0.006	0.013	-
Dividend Growth	-35.63%	-55.20%	-	-
Gross Margin	13.76%	14.95%	23.07%	10.33%
Operating Margin	8.10%	10.31%	19.86%	7.19%
Profit Margin	11.09%	11.99%	14.39%	6.31%
Free Cash Flow Margin	6.35%	12.37%	12.36%	-2.85%
EBITDA	6.17	8	9.48	2.04
EBITDA Margin	8.67%	10.71%	19.96%	7.30%
D&A For EBITDA	0.41	0.3	0.05	0.03
EBIT	5.76	7.7	9.43	2.01
EBIT Margin	8.10%	10.31%	19.86%	7.19%
Effective Tax Rate	13.13%	13.84%	20.47%	16.96%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.